This Web Site is committed to the memory of Janis Morrow.
54th Annual Meeting of
The American Association for
the Study of Liver Diseases
October 24, 28- 2003
Boston, Massachusetts
INDEX
|
Page One |
http://www.hivandhepatitis.com
Efficacy of Pegasys vs Pegasys
Plus Ribavirin in HIV-HCV Coinfected Patients Who Are Nonresponders to
Prior Interferon Therapy
10/27/03
Host Factors Responsible for a Viral Response May Be Different in
Responders Compared with Nonresponders and Independent of Serum
PEG-Intron Concentrations
10/27/03
HIV-HBV Coinfected Patients Show Sustained Suppression of
Epivir-HBV-resistant HBV Through 3 Years of Treatment with Hepsera
10/29/03
Report Confirms
Safety of Liver Transplantation in HIV-HCV Co-infected Patients
10/29/03
GB
Virus C (GBV-C) Clearance Is Frequent in HIV-HCV Coinfected Patients
Receiving Interferon and Ribavirin and Does Not Elevate HIV RNA Levels
10/29/03
HIV-HCV Coinfection Status Does Not Affect HCV Viral Kinetic Response to Interferon 11/10/03
Page Two
Viral Kinetics Can
Predict Sustained Viral Response to Treatment with Pegasys and
Ribavirin, independent of Genotype, as Early as 1 or 4 Weeks of
Treatment
10/27/03
A Comparison of Standard Treatment
Versus Dynamically Individualized Treatment in Patients with Chronic
Hepatitis C
10/27/03
Ribavirin Dosage
Significantly Affects Virological Response Rates in HCV Patients Treated
with Interferon/Ribavirin
10/27/03
Preliminary Data Do Not Support
Hypothesis That Higher SVR Rates in Genotype 1 HCV Patients Result from
Extending Treatment from 48 to 72 Weeks
10/27/03
Patients with Increased Symptoms of Depression During
Interferon/Ribavirin Therapy Are Less Likely to Clear HCV
10/27/03
Age and Adherence Are Significant Predictors of HCV Treatment Success 10/29/03
RANTES Haplotypes Predictive of Sustained Virological Response to HCV Treatment 10/31/03
Page Three
Viral Kinetics Can
Predict Sustained Viral Response to Treatment with Pegasys and
Ribavirin, independent of Genotype, as Early as 1 or 4 Weeks of
Treatment
10/27/03
Pegasys/Ribavirin
Treatment in African American and Caucasians with Chronic HCV Genotype 1
10/27/03
Pegasys/Ribavirin Enhances HCV
Specific T-cell Responses by Restoration of Dendritic Cell Functions
10/27/03
Preliminary Data Do Not Support
Hypothesis That Higher SVR Rates in Genotype 1 HCV Patients Result from
Extending Treatment from 48 to 72 Weeks
10/27/03
Subjects with Chronic Hepatitis C
and Genotype 4 Have a Similarly Effective Response to Standard or
Pegylated Interferon in Combination with Ribavirin
10/27/03
Pegasys Plus
Ribavirin Demonstrates Good Safety and Tolerability Profiles in African
Americans with Chronic HCV Genotype 1
11/03/03
Pegasys Plus
Ribavirin Produces a Benefit Regarding Histologic Response Among African
Americans and Caucasians with Chronic HCV Genotype 1
11/03/03
Page Four
Viral Kinetics Can
Predict Sustained Viral Response to Treatment with Pegasys and
Ribavirin, independent of Genotype, as Early as 1 or 4 Weeks of
Treatment
10/27/03
A Comparison of Standard Treatment Versus Dynamically Individualized
Treatment in Patients with Chronic Hepatitis C
10/27/03
HIV-HCV
Coinfection Status Does Not Affect HCV Viral Kinetic Response to
Interferon
11/10/03
Multivariate Models Predict Outcome of Therapy for HCV at Baseline and
at Weeks 4 and 8
11/07/03
HIV-HCV Coinfection Status Does Not Affect HCV Viral Kinetic Response to Interferon 11/10/03
Page Five
A Comparison of
Standard Treatment Versus Dynamically Individualized Treatment in
Patients with Chronic Hepatitis C
10/27/03
Treatment with
PEG-Intron Plus Ribavirin Is Effective in 50% of Relapsers to Standard
Combination Therapy
10/27/03
Treatment with PEG-Intron and Ribavirin Produces Significant Sustained
Virologic Response Rates in Patients Who Failed Prior Therapy
10/27/03
Weight-based Dosing of PEG-Intron
or Double the Dose Plus Ribavirin for Naïve Patients and Double Dose
PEG-Intron Plus Ribavirin for Nonresponders and Relapsers
10/27/03
Efficacy of Pegasys vs Pegasys
Plus Ribavirin in HIV-HCV Coinfected Patients Who Are Nonresponders to
Prior Interferon Therapy
10/27/03
Host Factors Responsible for a Viral Response May Be Different in
Responders Compared with Nonresponders and Independent of Serum
PEG-Intron Concentrations
10/27/03
HCV-specific
Immune Responses at Baseline Do Not Predict a Favorable Retreatment
Outcome in Patients with Advanced Disease
11/21/03
Page Six
Treatment Response
to Pegasys/Ribavirin Among Chronic HCV Patients with Normal ALT Levels
Is Similar to That Obtained Among Patients with Elevated ALT
10/27/03
Untreated Patients
with Chronic Hepatitis C (CHC) and Normal ALT Levels Have Distinct
Biological and Virological Features and a Majority Report CHC Symptoms
Associated with Interferon Treatment
10/27/03
Patients with Chronic Hepatitis C
and Normal ALT Levels Show Impaired Quality of Life But Significantly
Lower Liver Inflammation and Fibrosis Progression Compared to Patients
with Elevated ALT
10/27/03
Page Seven
Pegasys/Ribavirin Treatment in African American and Caucasians with Chronic HCV Genotype 1 10/27/03
Pegasys Plus Ribavirin Demonstrates Good Safety
and Tolerability Profiles in African Americans with Chronic HCV Genotype
1
11/03/03
Pegasys Plus
Ribavirin Produces a Benefit Regarding Histologic Response Among African
Americans and Caucasians with Chronic HCV Genotype 1
11/03/03
Untreated Patients
with Chronic Hepatitis C (CHC) and Normal ALT Levels Have Distinct
Biological and Virological Features and a Majority Report CHC Symptoms
Associated with Interferon Treatment
10/27/03
Patients with Increased Symptoms
of Depression During Interferon/Ribavirin Therapy Are Less Likely to
Clear HCV
10/27/03
Peginterferon Commonly Causes
Clinically Significant Depressive Symptoms, but Not Major Depression,
and Ribavirin May Contribute to Depression in a Dose-dependent Manner
10/27/03
Predictors
of Antiretroviral-related Severe Liver Toxicity in 21 AACTG Studies
11/07/03
Description
of Liver Toxicity Associated with HIV Protease Inhibitors with or
without Low-dose Ritonavir Boosting
11/07/03
Page Eight
Ribavirin Dosage
Significantly Affects Virological Response Rates in HCV Patients Treated
with Interferon/Ribavirin
10/27/03
Peginterferon Commonly Causes
Clinically Significant Depressive Symptoms, but Not Major Depression,
and Ribavirin May Contribute to Depression in a Dose-dependent Manner
10/27/03
Ribavirin Dosage
Significantly Affects Virological Response Rates in HCV Patients Treated
with Interferon/Ribavirin
10/27/03
Weight-based Dosing of PEG-Intron or Double the Dose Plus Ribavirin for
Naïve Patients and Double Dose PEG-Intron Plus Ribavirin for
Nonresponders and Relapsers
10/27/03
At 24 Weeks,
a Ribavirin Dose of 1000mg/day Appears to Offer No Advantages Over a
Dose of 800mg/day in HIV-HCV Coinfected Patients
11/10/03
As HAART
Therapy Prolongs Survival, More HIV-HCV Coinfected Individuals May
Experience Morbidity and Death from Progressive Liver Disease
11/07/03
PEG-Intron Plus Ribavirin Improves Histology and Fibrosis in
Nonresponders to Conventional Interferon and Ribavirin
11/07/03
Viral
Diversity and Immune Responses to HCV Do Not Correlate with Liver
Injury at a Single Time Point
11/21/03
HCV-specific Immune Responses at Baseline Do Not Predict a Favorable
Retreatment Outcome in Patients with Advanced Disease
11/21/03
BILN 2061 Establishes Proof-of-Concept in Humans for an HCV Protease Inhibitor 10/29/03
HCV Protease Inhibitor VX-950 Appears Effective in Early Studies 10/29/03
VX-950 Retains Potency Against BILN-2061-resistant Replicon Cells 10/29/03
HCV Polymerase Inhibitors Are Potential Drug Candidates for Treatment of HCV 10/29/03
RNA Interference: A New Strategy for HCV Treatment 10/31/03
RNA Interference Can Inhibit HCV Replication 10/31/03
Treatment
with Pirfenidone for One Year Produces a Significant Reduction in
Necroinflammation and Steatosis in Patients with Liver Cirrhosis
11/19/03
Viramidine, a Prodrug of Ribavirin, May Have Increased Efficacy and
Reduced Red Blood Cell Toxicity Compared to Ribavirin
11/14/03
Page 11
Page 10
HCV
NS3 and NS4 Proteins Contain Epitopes Associated with Spontaneous Viral
Clearance
10/29/03
Development of HCV-specific T Cells in HCV-exposed, HCV-Seronegative
Individuals
10/29/03
Sexual Transmission of HCV in Heterosexual, Monogamous Couples- The HCV Partners Study 10/29/03
Preemptive HCV Treatment Following Liver Transplantation May Improve Liver Histology 10/29/03
Therapy Intolerance Is Problematic in Patients with Recurrent HCV Following Liver Transplant10/31/03
Liver Transplant Outcomes in HCV-infected Patients Are Unchanged from 1991 to 2001 10/31/03
Preemptive Therapy May Provide Important Histological Benefits in
HCV Positive Liver Transplant Recipients
11/05/03
Patients with Recurrent HCV After Liver Transplantation Treated Have
High Rates of Intolerance to Therapy with Peginterferon Plus
Ribavirin
11/03/03
PEG-Intron Plus Ribavirin Appears to Improve the Clinical Course of
HCV Reinfection After Liver Transplantation
11/05/03
|
Characteristics and Outcomes of African Americans with Primary Hepatocellular Carcinoma in the US 11-05-03 |